- Home
- DENN vs PLRX Comparison
DENN vs PLRX Comparison
Compare DENN & PLRX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- DENN
- PLRX
- Stock Information
- Founded
- DENN 1953
- PLRX 2015
- Country
- DENN United States
- PLRX United States
- Employees
- DENN N/A
- PLRX N/A
- Industry
- DENN Restaurants
- PLRX Biotechnology: Pharmaceutical Preparations
- Sector
- DENN Consumer Discretionary
- PLRX Health Care
- Exchange
- DENN Nasdaq
- PLRX Nasdaq
- Market Cap
- DENN 203.4M
- PLRX 165.5M
- IPO Year
- DENN 1989
- PLRX 2020
- Fundamental
- Price
- DENN $3.82
- PLRX $1.41
- Analyst Decision
- DENN Strong Buy
- PLRX Hold
- Analyst Count
- DENN 6
- PLRX 10
- Target Price
- DENN $7.75
- PLRX $9.79
- AVG Volume (30 Days)
- DENN 1.5M
- PLRX 1.9M
- Earning Date
- DENN 04-29-2025
- PLRX 05-05-2025
- Dividend Yield
- DENN N/A
- PLRX N/A
- EPS Growth
- DENN 17.14
- PLRX N/A
- EPS
- DENN 0.41
- PLRX N/A
- Revenue
- DENN $452,334,000.00
- PLRX N/A
- Revenue This Year
- DENN $5.81
- PLRX N/A
- Revenue Next Year
- DENN $2.50
- PLRX N/A
- P/E Ratio
- DENN $9.30
- PLRX N/A
- Revenue Growth
- DENN N/A
- PLRX N/A
- 52 Week Low
- DENN $3.61
- PLRX $1.24
- 52 Week High
- DENN $8.85
- PLRX $16.52
- Technical
- Relative Strength Index (RSI)
- DENN 35.98
- PLRX 27.52
- Support Level
- DENN $3.61
- PLRX $1.24
- Resistance Level
- DENN $4.01
- PLRX $1.56
- Average True Range (ATR)
- DENN 0.17
- PLRX 0.12
- MACD
- DENN 0.05
- PLRX 0.22
- Stochastic Oscillator
- DENN 42.00
- PLRX 31.52
About DENN Denny's Corporation
Denny's Corp is one of America's franchised full-service restaurant chains based on the number of restaurants. The company owns and operates the Denny's brand and the Keke's Breakfast Cafe brand. It provides Pancakes, Appetizers & Soups, Sandwiches & Salads, Breakfast Melts, Omelets, and others. The company generates its revenue from two sources: the sale of food and beverages and the collection of royalties, advertising revenue, initial and other fees, including occupancy revenue, from restaurants operated by their franchisees.
About PLRX Pliant Therapeutics Inc.
Pliant Therapeutics Inc is a clinical-stage biopharmaceutical company focused on discovering and developing novel therapies for the treatment of fibrosis and related diseases. Its primary product candidate is bexotegrast (PLN-74809), an oral, small molecule, that the company is developing for the treatment of idiopathic pulmonary fibrosis, or IPF, and primary sclerosing cholangitis.